TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00213590
Drug: cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
Study: NCT00327145
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00327145
Drug: hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00327145
Drug: amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01509391
Drug: keyhole-limpet hemocyanin
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration keyhole-limpet hemocyanin
Study: NCT03050866
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2 q3w
Study: NCT03385135
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg for 4 weeks then 600 mg for 4 weeks in the active group
Study: NCT00736190
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300-mg tablet (marketed formulation) taken orally once daily
Study: NCT00835796
Drug: Finasteride 5 mg tablets
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 5 mg, single dose fasting
Study: NCT02095522
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 1mg per day for one month
Study: NCT02167594
Drug: Flortaucipir F18
Normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370 megabecquerel (MBq) (10 mCi)
Study: NCT01550302
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 37.5 mg of bupivacaine subcutaneously
Study: NCT03032315
Drug: TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)
Normalized name: Tahitian vanilla bean extract
DrugBank: Vanilla (DB10576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
Study: NCT03032315
Drug: TWYNSTA(Telmisartan+Amlodipine besylate)
Normalized name: amlodipine / telmisartan Oral Tablet [Twynsta]
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
Study: NCT03032315
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
Study: NCT01218230
Drug: Intravitreal Pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
Study: NCT02319044
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab monotherapy
Study: NCT02319044
Drug: MEDI4736 + Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 + Tremelimumab combination therapy
Study: NCT03045016
Drug: Prazosin, ALPRESS® LP 2,5 et 5 mg
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days.
Study: NCT02343627
Drug: Vehicle of test product
Normalized name: Dental Resources brand of Stannous Fluoride Dental Product
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
Study: NCT04147351
Drug: Atezolizumab Injection; bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a PD-L1 inhibitor; anti-angiogenesis
Study: NCT00362505
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04208698
Drug: CIN-102 Dose 1
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deuterated domperidone (deudomperidone)
Study: NCT04208698
Drug: CIN-102 Dose 2
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deuterated domperidone (deudomperidone)
Study: NCT00705653
Drug: PG-11047
Normalized name: PG
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
Study: NCT00576927
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
Study: NCT01608646
Drug: S-1 plus oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
Study: NCT00046228
Drug: abciximab placebo; reteplase placebo, abciximab, abciximab
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Study: NCT00014469
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00014469
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00014469
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04143880
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intramuscular injection intranasal administration
Study: NCT00602342
Drug: Terbinafine
Normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00965757
Drug: T-614
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
Study: NCT03807440
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin
Study: NCT03807440
Drug: Sodium Glucose Transporter 2 inhibitor
Normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Glucose Transporter 2 inhibitor
Study: NCT03807440
Drug: Dipeptidyl-peptidase 4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipeptidyl-peptidase 4 inhibitor
Study: NCT00531999
Drug: Raltegravir then lopinavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
Study: NCT00531999
Drug: Lopinavir/ritonavir then raltegravir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
Study: NCT00029614
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00225173
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
Study: NCT00225173
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
Study: NCT00225173
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
Study: NCT00225173
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
Study: NCT00225173
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1250 mg/m2 IV w 13,15,17,19
Study: NCT00225173
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 IV w 13,15,17,19
Study: NCT00225173
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 40 mg/m2 PO qod w 1-10, taper
Study: NCT02164812
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02164812
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03329950
Drug: CDX-1140
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
Study: NCT03329950
Drug: CDX-301
Normalized name: CDX-301
DrugBank: CDX-301 (DB19293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDX-301 will be injected once a day for five days before Cycles 1 and 2.
Study: NCT03329950
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab will be administered every 3 weeks.
Study: NCT00540826
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in-label use
Study: NCT00046228
Drug: Abciximab; reteplase; abciximab placebo; abciximab
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Study: NCT00046228
Drug: abciximab; reteplase placebo; abciximab placebo; abciximab
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Study: NCT00046228
Drug: abciximab placebo; reteplase placebo, abciximab, abciximab
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
Study: NCT03807440
Drug: Glucagon-like peptide 1 agonist
Normalized name: Glucagon-like peptide II (2-glycine) (human)
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon-like peptide 1 agonist
Study: NCT01747798
Drug: auranofin
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01217840
Drug: Drisdol (Ergocalciferol) Vitamin D2
Normalized name: ergocalciferol
DrugBank: Vitamin D (DB11094)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
Study: NCT04560725
Drug: 11C-Choline
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
Study: NCT00448825
Drug: Topiramate + Cognitive Behavioral Therapy
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate up to 300 mg per day
Study: NCT01394419
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
Study: NCT01394419
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equal volume of normal saline
Study: NCT01572623
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
Study: NCT01572623
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
Study: NCT01466855
Drug: Intra-Ophthalmic Artery Topotecan Infusion
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
Study: NCT00137748
Drug: CMV-Ig
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: CMV-Ig
Study: NCT00662363
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 µg po BID given with meals for 6 days
Study: NCT00662363
Drug: Senna
Normalized name: Senna
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tabs daily for 6 days
Study: NCT00215956
Drug: topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
Study: NCT01092754
Drug: Gadoversetamide
Normalized name: Gadoversetamide
DrugBank: Gadoversetamide (DB00538)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
Study: NCT00011076
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01754623
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
Study: NCT01754623
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
Study: NCT02016235
Drug: Phosphorus Supplement
Normalized name: Phosphorus supplement
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg po qid
Study: NCT01140438
Drug: metformin+ NPH insulin
Normalized name: INSULIN,NPH,BEEF
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
Study: NCT01140438
Drug: metformin + sitagliptin +/- repaglinide
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
Study: NCT01754623
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
Study: NCT01306591
Drug: Bevacizumab 1
Normalized name: bevacizumab 100 MG in 4 ML Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
Study: NCT01306591
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
Study: NCT04147221
Drug: Imipenem-relebactam
Normalized name: cilastatin / imipenem / relebactam
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
Study: NCT04086147
Drug: Low dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
Study: NCT04086147
Drug: High dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
Study: NCT03275376
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin or placebo will be administered according to randomized allocations.
Study: NCT00668577
Drug: Lactic acid (Dermacid)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01798004
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01798004
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00004105
Drug: estramustine phosphate sodium
Normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004105
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004105
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01798004
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01798004
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01798004
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01798004
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01798004
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02527213
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
Study: NCT01700725
Drug: Nasal Irrigation - Xylitol
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot.
Study: NCT03864432
Drug: Gemigliptin 25mg
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin 50mg 1/2T
Study: NCT03864432
Drug: Gemigliptin 50mg
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin 50mg 1T
Study: NCT03864432
Drug: Gemigliptin 100mg
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin 50mg 2T
Study: NCT04016753
Drug: BMS-986256
Normalized name: BMS-986256
DrugBank: Afimetoran (DB16580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg(6ml)
Study: NCT04016753
Drug: Loestrin
Normalized name: Lo Loestrin Fe
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg Norethindrone and 30ug ethinyl estradiol
Study: NCT01174303
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
Study: NCT01174303
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.